Highlights and Quick Summary
- Net Income for the quarter ending March 31, 2022 was $-10.2 Million (a 66.34% increase compared to previous quarter)
- Year-over-year quarterly Net Income increased by 13.59%
- Annual Net Income for 2021 was $-24.6 Million (a -18.93% decrease from previous year)
- Annual Net Income for 2020 was $-30.3 Million (a -15.48% decrease from previous year)
- Annual Net Income for 2019 was $-35.9 Million (a -65.16% decrease from previous year)
- Twelve month Net Income ending March 31, 2022 was $-32.7 Million (a 32.3% increase compared to previous quarter)
- Twelve month trailing Net Income increased by 26.23% year-over-year
Trailing Net Income for the last four month:
31 Mar '22 | 31 Dec '21 | 30 Sep '21 | 30 Jun '21 |
---|---|---|---|
$-32.7 Million | $-24.7 Million | $-23.1 Million | $-25.9 Million |
Visit stockrow.com/NVCN
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Net Income of Neovasc Inc.
Most recent Net Incomeof NVCN including historical data for past 10 years.Interactive Chart of Net Income of Neovasc Inc.
Neovasc Inc. Net Income for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
---|---|---|---|---|---|
2022 | $-10.16 | – | – | – | – |
2021 | $-6.11 | $-7.48 | $-8.94 | $-2.18 | $-24.57 |
2020 | $-4.54 | $-10.23 | $-9.93 | $-4.11 | $-30.31 |
2019 | $-12.35 | $-6.2 | $-7.96 | $-8.62 | $-35.86 |
2018 | $11.68 | $-14.64 | $-49.15 | $-55.88 | $-102.91 |
2017 | $-5.03 | $-4.7 | $-5.34 | $-7.85 | $-23.79 |
2016 | $37.21 | $-29.14 | $-83.69 | $-10.88 | $-86.49 |
2015 | $-8.01 | $-7.01 | $-6.75 | $-4.96 | $-26.73 |
2014 | $-6.75 | $-4.23 | $-5.94 | $-0.34 | $-17.18 |
2013 | $-2.19 | $-1.34 | $-1.18 | $-1.84 | $-6.55 |
2012 | $3.65 | $-1.25 | $-1.49 | $-1.26 | $-0.35 |
2011 | $-3.86 | – | – | – | $-3.86 |
Business Profile of Neovasc Inc.
Sector: Healthcare
Industry: Medical Devices
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.